Background: Tamoxifen, a selective estrogen receptor modulator, decreased airway neutrophilia
| INTRODUCTION
Severe equine asthma, also known as heaves or recurrent airway obstruction, is a common and incurable respiratory disease of adult horses. Exacerbations are triggered by inhalation of environmental antigens, most commonly those found in hay. The disease is characterized by airway hyper-responsiveness, mucus hypersecretion, intraluminal neutrophilia, and structural changes affecting the airways (remodeling). 1 Through the release of pro-inflammatory mediators, proteases, and extracellular traps, neutrophils are potentially major perpetuators of lung damage 2, 3 and their presence has been associated with the dysfunction of peripheral airways in asthmatic patients. 4 Usual therapies (corticosteroids and bronchodilators), while improving the lung function, do not normalize airway luminal neutrophilia and tissue remodeling of asthmatic horses. 5, 6 Furthermore, clinical signs relapse quickly after cessation of medication. 7 Although antigen avoidance controls airway inflammation, pulmonary remodeling is incompletely reversed even after a year at pasture. 5 Therefore, therapies targeting airway neutrophilia are required to determine if control of pulmonary inflammation can improve lung function and remodeling in severe equine asthma. 8 Tamoxifen is a synthetic selective estrogen receptor modulator.
Because of its antagonism of estrogen-dependent growth and its inhibitory effect on breast epithelial cells proliferation, its major use has been in the treatment of breast cancer. 9, 10 Nonetheless, tamoxifen appears to have a broader spectrum of activity as it showed beneficial effects in estrogen-receptor negative cancers, in selected
Abbreviations: BALF, bronchoalveolar lavage fluid; CI, 95% confidence interval; E L , pulmonary elastance; NETs, neutrophil extracellular traps; P L , transpulmonary pressure; R L , pulmonary resistance immune disorders, and potentially in spinal cord injury. [11] [12] [13] [14] As estrogen administration has been associated with both improvement and, contrariwise, to the development of asthma in women, studying the impact of an estrogen receptor modulator could help delineate the role of sex hormones in asthma. 15, 16 Recently, it showed promising results for the treatment of severe equine asthma by reducing the neutrophilic chemotactic response and respiratory burst production and by inducing apoptosis of peripheral and pulmonary neutrophils in vitro. 17, 18 Tamoxifen was also studied in healthy adult horses in which an asthma-like inflammation was experimentally reproduced by exposure to Aspergillus fumigatus contaminated hay. In this experiment, tamoxifen increased the apoptosis of peripheral and pulmonary neutrophils and improved clinical condition, airway neutrophilia, and mucus accumulation. 19 We therefore hypothesized that tamoxifen, by decreasing airway neutrophilia, would improve the lung function of severely asthmatic horses. These objectives were to study the effects of tamoxifen on airway luminal inflammation, on tracheal mucus accumulation and on pulmonary function testing of asthmatic horses during continuous antigen exposure. 
| MATERIALS AND METHODS

| Ethics statement
| Animals
Twelve severe asthmatic horses (7 mares and 5 geldings) from this research herd were studied. Horses were mixed breeds, aged 14 AE 4 years and weighed 514 AE 51 kg. The horses were diagnosed with severe asthma based on history and previous results of pulmonary function and bronchoalveolar lavage fluid (BALF) cytology. These horses had historically >25% neutrophils on BALF cytology and a transpulmonary pressure (P L ) change above 15 cm of H 2 O when stabled and fed hay and airway obstruction was reversible by antigen avoidance. The presence of a concomitant medical condition was excluded with a physical examination and complete blood count.
To induce chronic exacerbation of the disease as seen in clinical practice, the animals were stabled 3 weeks before the study and were fed dry timothy hay and sweet feed twice daily. The management remained the same throughout the study period. No treatment was administered at least 7 weeks before the trial. Horses were conditioned to wear a mask and to stand in a stock. 
| Pulmonary function tests
| Study protocol
After randomization based on pulmonary resistance ranking value, six were performed before treatment on day 1, and on days 6 and 13.
Endoscopic tracheal mucus scores and bronchoalveolar lavages were performed on days 1 and 13. The attitude, appetite, and a clinical respiratory score 21 were evaluated daily by a blinded investigator.
| Statistical analysis
Bronchoalveolar lavage, lung function, and the clinical respiratory score data were analyzed with repeated-measures two-way ANOVA with "group" as the between-subject factor and "time" (days of treatment) as the within-subject factor with Bonferroni corrections for multiple comparisons. Mucus scores were evaluated within each treatment group with Wilcoxon matched-pairs signed rank tests and among treatment groups with Mann-Whitney U tests. Data are described as mean difference with 95% confidence interval (CI).
P values <.05 were considered statistically significant. GraphPad Prism 7 (GraphPad Prism 7, GraphPad Software, Inc, La Jolla, California) was used for statistical calculations.
| RESULTS
No adverse effect was observed in the tamoxifen group. On the ninth day of treatment, a horse treated with dexamethasone developed hypocalcemic and hypomagnesemic tetany unresponsive to treatment. Euthanasia was humanely elected for this animal and at necropsy, loss of the principal cells of the parathyroid gland was observed. The exact cause of this finding was undetermined. All data from that horse were excluded from analysis.
| Pulmonary function tests and clinical respiratory scores
Horses were in clinical exacerbation of the disease at baseline (P L > 15 
| BALF cytology
At the beginning of the study, the percentage of neutrophils in the BALF was above normal (>5%) in 10 of the 11 remaining horses. The horse lacking airway neutrophilia was excluded from analysis concerning BALF cytology. The two-way ANOVA showed a group effect (P = .02) which was possibly related to a higher neutrophilia at baseline in the tamoxifen 
| DISCUSSION
The results of this randomized controlled study failed to detect an effect of a short-term treatment with tamoxifen on airway neutrophilia in
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severe asthmatic horses, refuting this hypothesis. A statistically significant diminution, but not a normalization, of airway resistance was observed, without improvement of the pulmonary elastance. As expected, dexamethasone normalized lung function while neither reducing airway inflammation 6 nor macroscopic mucus accumulation 22 .
Tamoxifen's effectiveness in the treatment of breast cancer is partly attributed to the apoptosis of tumor cells mediated by oxidative stress and increased ceramide intracellular level among other mechanisms. 23 Tamoxifen also causes ceramide intracellular accumulation in neutrophils 24 , therefore, we suspected that it could lead to neutrophilic apoptosis and concurrent improvement of airway inflammation.
However, we did not observe a decrease of airway neutrophilia with tamoxifen which contrasts with previous reports. Indeed, in one study, tamoxifen administered every other day for three doses reduced experimentally induced intraluminal inflammation in healthy horses. 19 However, the pathways responsible for neutrophil accumulation in healthy horses after hay exposure likely differ from that of asthmatic horses which might explain these different results. In addition, because the airway neutrophilia is transient when hay is introduced to healthy horses and considering that antigenic exposure was ceased when the treatment was initiated, the improvement reported might have been the normal kinetic of airway inflammation regulation, rather than an effect of tamoxifen. 25 Moreover, the duration of the antigenic challenge was of a short duration (1 week) when compared with this study (3 weeks), which could have contributed the discordance of the results. The chronicity of the exacerbation in this study could have impeded the anti-inflammatory efficacy of this medication. However, to be useful clinically, a treatment would have to be effective under these conditions.
The effects of tamoxifen on neutrophils are controversial with in vitro studies suggesting an anti-inflammatory effect by the induction of apoptosis, a reduction of the chemotactic response and respiratory burst production, a decreased production of 5-lipoxygenase and a diminution of the neutrophilic infiltration to the site of injury. [17] [18] [19] 26, 27 In contrast, other experiments have shown activation of neutrophils by an enhancement of their chemotaxis, phagocytic and bactericidal activity, and neutrophil extracellular traps (NETs) formation. 24 Because aberrant NETs production is a feature of human and equine asthma, medications increasing their formation might be detrimental for the treatment of this condition. 3, 28 Furthermore, it has been suggested that the immunomodulation associated with tamoxifen is mediated by a shift from a Th1 to a Th2 response, possibly related to an inhibition of the maturation of dendritic cells.
11,29
Because a predominant Th2-type response has been associated with exacerbation in severe equine asthma, at least in some horses 30, 31 , a shift in cellular signaling might explain the lack of efficacy in this study. Of note, a case report describes human asthma exacerbations induced by tamoxifen, but the mechanisms of those deteriorations were not determined. 32 Taken together, the usefulness of this medication raises interrogations in a disease where immunological pathways involved are complex and incompletely understood.
The main limitation of this trial is the small number of horses which might have precluded the detection of small differences in the airway neutrophilia, the primary outcome of this study. In addition, the mild neutrophilia (<25%) observed in five horses in the present trial could have reduced our capacity to identify improvement of luminal inflammation. Even though the BALF cytology is a mainstay in asthma diagnosis, the degree and onset of neutrophilic influx might not be constant. 33 From these five horses, only one had airway neutrophilia defined as normal (<5%) despite its disease being well charac- Daily clinical respiratory scores (means and standard deviations) from day 1 (before administration of medication) to day 13 of treatment with tamoxifen (black circles) and dexamethasone (white circles). *P < .05; **P < .01; ***P < .001 (significant differences from baseline) FIGURE 5 Tracheal mucus scores on day 1 (before administration of medication) and day 13 of treatment with tamoxifen (black circles) and dexamethasone (white circles)
to the dosage used for breast-cancer treatment. 10, 19 The pharmacoki- , whereas others suggest a detrimental effect of this sex hormone 16 . Therefore, an estrogen-mediated bronchodilation would be a possible explanation for the reduced R L observed in this study, however more research on the role of sex hormones in asthma is required. Alternatively, the bronchodilation could have been mediated by an interaction with calcium-channels. A reduction of vascular smooth muscle cell contractility has been reported with tamoxifen and the authors suggested that the effect might be related to an inhibition of voltage-dependant calcium channels. 35 Consistent with the favorable safety profile of tamoxifen in humans, we did not observe adverse events with a short-term administration. Reported adverse effects after prolonged use include endometrial cancers and thromboembolic accidents. 9 The refractory hypocalcemic and hypomagnesemic tetany observed in a dexametha- 
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